Get all your news in one place.
100's of premium titles.
One app.
Start reading
WEKU
WEKU
Health
Rob Stein

BIZARRE: Crispr gene editing may boost cancer immunotherapy new study finds - You Need To See This

Katie Pope Kopp, 64, of Parkville, Mo., at Union Station in Kansas City this week. Kopp underwent a new form of experimental CAR T-cell therapy that used the CRISPR gene-editing technique to treat her non-Hodgkin lymphoma. The cancer has been in remission for over a year. (Barrett Emke for NPR)

Katie Pope Kopp went through round after round of chemotherapy and a stem cell transplant to treat her non-Hodgkin lymphoma. But nothing could beat it.

"I went back to get a PET scan in May of 2020, and that's when they found that my non-Hodgkin's had blown back up, which was very disappointing," says Kopp, 64, of Parkville, Mo. She was originally diagnosed five years ago.

Victor Bartolome suffered through decades of chemotherapy and a stem cell transplant, too, to keep his blood cancer at bay. Eventually, his doctors told him he had run out of options.

"That was devastating. Imagine having what you think is your last hope pulled out from under you," says Bartolome, 74, of Santa Barbara, Calif.

But then Kopp and Bartolome heard about something new: In the last few years, some doctors have started using the gene-editing technique CRISPR to try to modify cells of the immune system to treat cancers like theirs.

Kopp jumped at the chance to volunteer for a study testing the approach, even though she says she's a tarot card reader who long relied on homeopathy instead of mainstream medicine.

"I'm like: 'Yeah. Sign me up. I'll be your guinea pig,' " she says, laughing.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.